Advertisement

Topics

Genzyme, a Sanofi Company Company Profile

01:30 EDT 20th September 2018 | BioPortfolio

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com.


News Articles [775 Associated News Articles listed on BioPortfolio]

Sanofi Genzyme’s foray into Indian MS market should be met with caution, says GlobalData

Sanofi Genzyme — specialty care global business unit of French pharma company Sanofi — has launched its multiple sclerosis (MS) drug in India, however, according to GlobalData, it should be cautio...

Sanofi turns down option to develop lumasiran

Alnylam Pharmaceuticals says that Sanofi Genzyme, the biotech unit of French pharma major Sanofi has…

Sanofi Genzyme Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 19022018] Prices from USD $350

Sanofi Genzyme Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Sanofi Genzyme Mergers Acquisitions MA, Partnerships Alliances and Investments report inclu...

Sanofi Genzyme Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 26062018] Prices from USD $350

Sanofi Genzyme Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Sanofi Genzyme Mergers Acquisitions MA, Partnerships Alliances and Investments report inclu...

Sanofi Quarterly Sales Sluggish with Focus on Integrating Bioverativ and Ablynx

Paris-based Sanofi reported mixed first-quarter revenues, with net sales down 8.7 percent to 7,898 million euros. But Sanofi Genzyme sales were up 16.2 percent, mostly the result of its new immunology...

Sanofi-Genzyme BioVentures leads $10mm funding round for Evidation

Digital health company Evidation Health Inc. (behavior-driven outcome measurement products that use real life patient data from hundreds of applications and devices to assess a patient's best therapeu...

Sanofi bets big on India

The specialty care global business unit, Sanofi Genzyme, has recently launched its multiple sclerosis drug, in India

Sanofi passes on Alnylam's breakthrough therapy

Alnylam is to forge ahead with a rare disease therapy on its own after Sanofi decided to opt out of a co-development and co-marketing deal. Sanofi, and its rare disease arm Genzyme, has opted out of ...

PubMed Articles [29 Associated PubMed Articles listed on BioPortfolio]

Characteristics of Occupational Injuries in a Pharmaceutical Company in Iran.

To prioritize occupational hazards in a Pharmaceutical Company in Iran using the analytical hierarchy process (AHP).

A Man (or a Woman) is Known by the Company He/She Keeps.

McGoldrick, M. (2016). The genogram casebook: A clinical companion to genograms: Assessment and intervention. New York, NY: W.W. Norton & Company, 304 pp., $32.00.

Significant Decreasing Trend in Low Back Injuries in a Beverage Company.

Work-related injuries in the U.S. have steadily declined over the past three decades.

Dupixent, a New Entrant In the Asthma Lists.

Sanofi and Regeneron's Dupixent (dupilumab)-which is already approved for atopic dermatitis-has an FDA action date of October 20 for its asthma indication. It will join Nucala, (mepolizumab), Cinqair ...

Clinical Trials [165 Associated Clinical Trials listed on BioPortfolio]

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Primary objectives: - To describe the immune response to each dengue serotype before and after each vaccination with sanofi pasteur's CYD dengue vaccine. - To evaluate t...

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. T...

Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

The purpose of this study is to determine the safety and efficacy of Busulfan/FLAG (fludarabine, cytarabine and granulocyte colony-stimulating factor) Conditioning Regimen in Patients with...

Immunogenicity and Safety of Kinrix + MMR With and Without Varicella Vaccine in Healthy Children 4-6 Years

The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® [varicella virus vaccine live], Merck and Company) and MMR va...

A Study to Compare Subject Comfort During and After Injections With the Study Products and the Safety of the Non-FDA Approved Product for the Correction of Nasolabial Folds (NLFs)

The purpose of this research study is to compare subject comfort during and after injection with NADGL and Captique® Injectable Gel, in the nasolabial folds. Captique® is an FDA-approve...

Companies [1510 Associated Companies listed on BioPortfolio]

Genzyme, a Sanofi Company

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals t...

Sanofi and Warp Drive Bio

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human va...

SANOFI

SANOFI concentrate their research efforts where the most pressing medical needs and public health issues are, bringing solutions to patients and contributing to a healthier society worldwide: D...

Sanofi Genzyme

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, prov...

sanofi-aventis U.S.

Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. San...

More Information about "Genzyme, a Sanofi Company" on BioPortfolio

We have published hundreds of Genzyme, a Sanofi Company news stories on BioPortfolio along with dozens of Genzyme, a Sanofi Company Clinical Trials and PubMed Articles about Genzyme, a Sanofi Company for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Genzyme, a Sanofi Company Companies in our database. You can also find out about relevant Genzyme, a Sanofi Company Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Corporate Database Quicklinks



Searches Linking to this Company Record